You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

472 Results
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Oct 2024
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
May 2018
Guidelines and Advice

Pages